We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Health-Related Quality-of-Life Findings for the Prostate Cancer Prevention Trial.
- Authors
Moinpour, Carol M.; Darke, Amy K.; Donaldson, Gary W.; Cespedes, Duane; Johnson, Christine R.; Ganz, Patricia A.; Patrick, Donald L.; Ware, John E.; Shumaker, Sally A.; Meyskens, Frank L.; Thompson, Ian M.
- Abstract
Background The Prostate Cancer Prevention Trial (PCPT)—a randomized placebo-controlled study of the efficacy of finasteride in preventing prostate cancer—offered the opportunity to prospectively study effects of finasteride and other covariates on the health-related quality of life of participants in a multiyear trial. Methods We assessed three health-related quality-of-life domains (measured with the Health Survey Short Form–36: Physical Functioning, Mental Health, and Vitality scales) via questionnaires completed by PCPT participants at enrollment (3 months before randomization), at 6 months after randomization, and annually for 7 years. Covariate data obtained at enrollment from patient-completed questionnaires were included in our model. Mixed-effects model analyses and a cross-sectional presentation at three time points began at 6 months after randomization. All statistical tests were two-sided. Results For the physical function outcome (n = 16 077), neither the finasteride main effect nor the finasteride interaction with time were statistically significant. The effects of finasteride on physical function were minor and accounted for less than a 1-point difference over time in Physical Functioning scores (mixed-effect estimate = 0.07, 95% confidence interval [CI] = −0.28 to 0.42, P = .71). Comorbidities such as congestive heart failure (estimate = −5.64, 95% CI = −7.96 to −3.32, P < .001), leg pain (estimate = −2.57, 95% CI = −3.04 to −2.10, P < .001), and diabetes (estimate = −1.31, 95% CI = −2.04 to −0.57, P < .001) had statistically significant negative effects on physical function, as did current smoking (estimate = −2.34, 95% CI = −2.97 to −1.71, P < .001) and time on study (estimate = −1.20, 95% CI = −1.36 to −1.03, P < .001). Finasteride did not have a statistically significant effect on the other two dependent variables, mental health and vitality, either in the mixed-effects analyses or in the cross-sectional analysis at any of the three time points. Conclusion Finasteride did not negatively affect SF–36 Physical Functioning, Mental Health, or Vitality scores.
- Subjects
PROSTATE cancer patients; CANCER prevention; CANCER patients; PLACEBOS; CLINICAL trials
- Publication
JNCI: Journal of the National Cancer Institute, 2012, Vol 104, Issue 18, p1373
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djs359